What You Should Know:
- Verix, a leader in AI-powered commercial operations solutions for the pharmaceutical industry, has announced the launch of its revolutionary GenAI Database Explorer.
- The GenAI-powered tool empowers sales reps with the ability to explore complex commercial data using natural language processing (NLP), marking a significant step forward in data accessibility and insights generation.
Empowering Sales Teams with Natural Language Queries
Verix's flagship
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Pharmacovigilance in Crisis: Automation as the Answer to Workforce Shortages
The healthcare industry is no stranger to workforce shortages, and the pharmaceutical industry may be next to experience disruptions brought on by labor challenges. According to the U.S. Bureau of Labor Statistics, it is estimated that occupations across life, physical and social sciences are expected to grow 7% by 2028. However, statistics also indicate that about 136,800 openings in these fields will remain unfilled annually through 2032, as employment growth and worker resignations are
Read More
Chan Zuckerberg Initiative Forms AI Advisory Group & Residency Program to Develop Virtual Cell Models
What You Should Know:
- The Chan Zuckerberg Initiative (CZI) announced the formation of a powerful AI Advisory Group and an in-house AI residency program, both focused on building predictive models of healthy and diseased cells – a key step towards creating virtual cell models.
AI Advisory Group Background & Members
CZI's newly established AI Advisory Group will provide invaluable guidance and cross-disciplinary insights to CZI and the Chan Zuckerberg Biohub Network to push the
Read More
Cybin Raises $150M to Advance Psychedelic Therapy for Depression
What You Should Know:
- Cybin Inc. (NYSE American: CYBN), a company developing next-generation psychedelic therapies for mental health, has secured $150M in a private placement of common shares led by Deep Track Capital and included participation from other institutional investors. The price per share was set at $0.43, representing a 17% premium over the 10-day volume-weighted average trading price.
- The funding will fuel the development of CYB003, a potential first-in-class psychedelic
Read More
AstraZeneca Acquires Fusion Pharmaceuticals for $2B to Bolster Radioconjugate Pipeline
What You Should Know:
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.
AstraZeneca's Acquisition of Fusion:
Read More
Komodo Launches Self-Service App for Pharma Research
What You Should Know:
Today, Komodo Health unveiled a new self-service solution for rapid patient cohort analysis and insight generation.MapView is the industry’s first and most sophisticated analytics application that allows users without data science expertise to easily extract insights from Komodo’s Healthcare Map. MapView is designed to accelerate decision-making across the Life Sciences enterprise by generating powerful, automated business intelligence for every team and
Read More
QDx Pathology Services Deploys Proscia’s Pathology Platform To Improve Speed & Precision
What You Should Know:
QDx Pathology Services, an independent anatomical, molecular, and clinical pathology laboratory serving medical professionals and facilities throughout the United States, is working with Proscia®, a leading provider of digital and computational pathology solutions, to innovate its practice.The laboratory has deployed Proscia’s software to enable its pathologists to work faster and more confidently.
Revolutionizing Pathology: Proscia's Digital Solutions
Read More
Tempus Donates Over 3,000 Cancer Patient Profiles to Fuel National Cancer Institute Research
What You Should Know:
- Tempus, a leader in artificial intelligence and precision medicine, announced a groundbreaking data contribution to the National Cancer Institute (NCI) today.
- The first-of-its-kind contribution will significantly enhance the NCI's planned Data Enclave, a secure repository designed to accelerate cancer research.
Unlocking Insights from 3,000 Cancer Diagnoses
Tempus is donating de-identified tumor profiles with limited associated clinical information from over
Read More
Zephyr AI Secures $111M to Democratize Precision Medicine with Explainable AI
What You Should Know:
- Zephyr AI, a healthcare technology company pioneering explainable AI (XAI) for precision medicine, raises $111M in Series A round led by Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group.
- The company plans to use this round of funding to refine its technology to fortify its extensive collection of training and validation datasets, crucial for robust AI models, deliver results even faster, and expand its scientific and commercial
Read More
Pi Health Secures $30M to Democratize Cancer Clinical Trials
What You Should Know:
- Pi Health, a newly independent oncology-focused clinical research company raises $30M in Series A funding led by AlleyCorp and Obvious Ventures, with additional investments from Invus Capital and leaders in oncology from across the globe.
- The company, previously incubated by BeiGene (NASDAQ: BGNE), aims to revolutionize access to innovative cancer treatments through its technology platform and global network of clinical trial sites.
Less Than 8% of
Read More
